使用纳米颗粒疫苗提高针对流感漂移变异株的抗体滴度。 - Suppr

Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine.

作者信息

Shinde Vivek, Fries Louis, Wu Yukun, Agrawal Sapeckshita, Cho Iksung, Thomas D Nigel, Spindler Michelle, Lindner Elizabeth, Hahn Timothy, Plested Joyce, Flyer David, Massare Michael J, Zhou Bin, Fix Amy, Smith Gale, Glenn Gregory M

机构信息

Novavax, Gaithersburg, MD.

出版信息

N Engl J Med. 2018 Jun 14;378(24):2346-2348. doi: 10.1056/NEJMc1803554.

DOI:10.1056/NEJMc1803554

PMID:29897849

Abstract

摘要

相似文献

Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine.

N Engl J Med. 2018 Jun 14;378(24):2346-2348. doi: 10.1056/NEJMc1803554.

Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.

J Virol. 2017 Nov 30;91(24). doi: 10.1128/JVI.01581-17. Print 2017 Dec 15.

Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.

Intervirology. 2007;50(1):58-62. doi: 10.1159/000096314. Epub 2006 Nov 24.

[Characterization of a nonspecific inhibitor found in human sera raised against the 2006/07 influenza vaccine strain A/Hiroshima/52/2005 (H3N2) virus].

Kansenshogaku Zasshi. 2012 Jul;86(4):400-4. doi: 10.11150/kansenshogakuzasshi.86.400.

Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.

Vaccine. 2017 Sep 25;35(40):5366-5372. doi: 10.1016/j.vaccine.2017.08.021. Epub 2017 Aug 22.

Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine.

Vaccine. 2006 Aug 14;24(33-34):5966-9. doi: 10.1016/j.vaccine.2006.05.009. Epub 2006 May 26.

A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.

Antiviral Res. 2017 Apr;140:62-75. doi: 10.1016/j.antiviral.2017.01.010. Epub 2017 Jan 14.

Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.

AIDS. 2013 Jan 28;27(3):369-79. doi: 10.1097/QAD.0b013e32835ab5b2.

Universal influenza vaccines, science fiction or soon reality?

Expert Rev Vaccines. 2015;14(10):1299-301. doi: 10.1586/14760584.2015.1060860. Epub 2015 Jun 23.

Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.

Adv Exp Med Biol. 2016;897:45-53. doi: 10.1007/5584_2015_5003.

引用本文的文献

Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates.

Nat Commun. 2025 Jul 18;16(1):6625. doi: 10.1038/s41467-025-61964-y.

Revolutionizing Nanovaccines: A New Era of Immunization.

Vaccines (Basel). 2025 Jan 27;13(2):126. doi: 10.3390/vaccines13020126.

Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.

NPJ Vaccines. 2024 Jan 20;9(1):17. doi: 10.1038/s41541-024-00806-2.

The Matrix-M™ adjuvant: A critical component of vaccines for the 21 century.

Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885. Epub 2023 Apr 27.

Smart Nanostructured Materials for SARS-CoV-2 and Variants Prevention, Biosensing and Vaccination.

Biosensors (Basel). 2022 Dec 5;12(12):1129. doi: 10.3390/bios12121129.

Advances in Infectious Disease Vaccine Adjuvants.

Vaccines (Basel). 2022 Jul 13;10(7):1120. doi: 10.3390/vaccines10071120.

Controlled Human Infection Models To Accelerate Vaccine Development.

Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821. doi: 10.1128/cmr.00008-21. Epub 2022 Jul 6.

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.

Front Immunol. 2022 May 19;13:878943. doi: 10.3389/fimmu.2022.878943. eCollection 2022.

COVID-19 and Seasonal Influenza Vaccination: Cross-Protection, Co-Administration, Combination Vaccines, and Hesitancy.

Pharmaceuticals (Basel). 2022 Mar 8;15(3):322. doi: 10.3390/ph15030322.

Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform.

Nano Res. 2022;15(3):2196-2225. doi: 10.1007/s12274-021-3832-y. Epub 2021 Oct 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献